Natural Polymorphisms in *Mycobacterium tuberculosis* Conferring Resistance to Delamanid in Drug-Naive Patients

Martina L. Reichmuth, a Rico Hömke, b,c Kathrin Zürcher, a Peter Sander, b,c Anchalee Avihingsanon, d Jimena Collantes, e Chloé Loiseau, f,g Sonia Borrell, f,g Miriam Reinhard, f,g Robert J. Wilkinson, h,i,j Marcel Yotebieng, k,l Erik C. Böttger, b,c Sebastien Gagneux, f,g Matthias Egger, h,m Peter M. Keller b,c,n on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA)

a Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
b Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
c Swiss National Center for Mycobacteria, Zurich, Switzerland
d The HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre and Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
e Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
f Swiss Tropical and Public Health Institute, Basel, Switzerland
g University of Basel, Basel, Switzerland
h Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, Republic of South Africa
i Department of Infectious Diseases, Imperial College, London, United Kingdom
j The Francis Crick Institute, London, United Kingdom
k National TB Lab, Kinshasa, Democratic Republic of the Congo
l Albert Einstein College of Medicine, New York, New York, USA
m Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, Republic of South Africa
n Institute for Infectious Diseases, University of Bern, Bern, Switzerland

Martina L. Reichmuth and Rico Hömke contributed equally to this work. Author order was determined by decreasing seniority.

**ABSTRACT** Mutations in the genes of the F420 signaling pathway of *Mycobacterium tuberculosis* complex, including *dnn*, *fgd1*, *fbiA*, *fbiB*, *fbiC*, and *fbiD*, can lead to delamanid resistance. We searched for such mutations among 129 *M. tuberculosis* strains from Asia, South America, and Africa using whole-genome sequencing; 70 (54%) strains had at least one mutation in one of the genes. For 10 strains with mutations, we determined the MIC of delamanid. We found one strain from a delamanid-naive patient carrying the natural polymorphism Tyr29del (*ddn*) that was associated with a critical delamanid MIC.

**KEYWORDS** *Mycobacterium tuberculosis*, delamanid, resistance, mutations, drug resistance, natural polymorphism

In 2014, the new antituberculosis (anti-TB) drug delamanid (also known as OPC-67683, or Deltyba) was introduced (1). The World Health Organization (WHO) recommends the administration of delamanid if a standard effective drug regimen cannot be prescribed due to drug toxicity or resistance (2, 3). Thus, the European Medicines Agency (EMA) conditionally approved delamanid for the treatment of multidrug-resistant (MDR) TB (1, 3, 4). Of note, 6 years after its market launch, robust and widely accepted breakpoints that define susceptibility and resistance to delamanid still do not exist (5). The few available studies suggest a critical MIC between 0.125 mg/liter and 0.2 mg/liter, and an epidemiological cutoff value (ECOFF) of 0.04 mg/liter (6–9). This ECOFF is in line with the WHO technical report (10).

Delamanid is a drug of the bicyclic nitroimidazole class with potent anti-TB activity (1, 11). It is a prodrug that is activated by the deazaflavin (F420)-dependent nitroreduc-
tase (*ddn*) through hydride transfer, forming unstable intermediates, which in turn lead to the formation of reactive nitrogen species (nitric oxide, nitrous acid) (12, 13). Activated delamanid thus has a dual bactericidal mode of action: the primary decomposition product prevents mycolic acid synthesis, while the reactive nitrogen species cause respiratory poisoning (12–15). Loss-of-function mutations in *ddn* or one of the genes encoding the five coenzymes (*fgd1*, *fbiA*, *fbiB*, *fbiC*, and *fbiD*) have been proposed as a mechanism of resistance to delamanid (12, 13, 16, 17). In vitro, the frequencies of delamanid resistance-conferring mutations in the *Mycobacterium tuberculosis* laboratory strain H37Rv and in *Mycobacterium bovis* range from $2.51 \times 10^{-5}$ to $6.44 \times 10^{-6}$ (13). Previous studies have found several resistance-conferring mutations, including Leu107Pro (*ddn*), 51–101del (*ddn*), Trp885STOP (*ddn*), Gly81Asp (*ddn*), Gly81Ser (*ddn*), Gly53Asp (*ddn*), c.146_147insC (*fgd1*), Arg175His (*fbiA*), Gln88Glu (*fgd1*), Lys250STOP (*fbiA*), and Val318le (*fbiC*) (6–8, 18–22).

This multicenter study has been described in detail elsewhere and is part of the work of the International epidemiology Databases to Evaluate AIDS (IeDEA) (23). We identified putative delamanid resistance-conferring mutations in *M. tuberculosis* strains from TB patients living with HIV (PLWH) and delamanid-naive, HIV-negative TB patients by whole-genome sequencing (WGS) and MIC determination. We collected information on the demographic and clinical characteristics of patients who were recruited between 2013 and 2016 in Peru, Thailand, Côte d’Ivoire, the Democratic Republic of the Congo (DRC), Kenya, and South Africa (24, 25). The Cantonal Ethics Committee in Bern, Switzerland, and local institutional review boards approved the study. Written informed consent was obtained at all locations, except in South Africa, where consent was not required for archived samples.

The sequencing pipeline has been described previously (25). In brief, *M. tuberculosis* DNA was extracted and sequenced using the Illumina HiSeq 2500 system (Illumina, San Diego, CA, USA). For the analysis, we used the well-established pipeline TBprofiler ([https://github.com/jodyphelan/TBProfiler](https://github.com/jodyphelan/TBProfiler)) (26, 27). It aligns short reads to the *M. tuberculosis* reference strain H37Rv (GenBank accession no. NC_000962.3) with bowtie2 (v2.3.5), BWA (v0.7.17), or minimap2 (v2.16) and then calls variants with SAMtools (v1.9) (28–31). To identify putative delamanid resistance-conferring mutations, we analyzed *F420* genes (*ddn*, *fgd1*, *fbiA*, *fbiB*, *fbiC*, and *fbiD*) with variant frequencies of $\geq$75%. A subset of *M. tuberculosis* strains with at least one mutation in the *F420* genes was recultured in liquid medium and subjected to delamanid MIC determination (see Fig. S1 in the supplemental material). We assumed that 0.04 mg/liter indicates a critical MIC (9).

We included 129 *M. tuberculosis* isolates, among them 51 isolates (39.5%) from Peru, 13 (10.1%) from Thailand, 49 (38%) from Côte d’Ivoire, 14 (10.9%) from the DRC, and 1 (0.8%) each from Kenya and South Africa. We identified 70 (54.3%) isolates with polymorphisms in at least one of the six *F420* genes compared to the reference genome (Table S1). All patients infected with either of these strains were naive to delamanid. We selected strains fulfilling the following criteria: (i) mutations in a part of the gene encoding regions of catalytic or structural importance predicted by ARIBA and then the PhyResSE pipeline (32, 33), (ii) availability of a culture of the strain, and (iii) bacterial growth amenable to microdilution (25). MICs were determined for 10 isolates with mutations in the *F420* genes. Four isolates showed MICs of $\geq$0.015 mg/liter: specifically, MICs of 0.5 (patient 1), 0.03 (patients 6 and 10), and $>8$ (patient 9) mg/liter (Table 1; Fig. S1). The isolate from patient 1 had a polymorphism in *fgd1* (Lys270Met) and was susceptible to the six drugs tested (isoniazid, rifampin, ethambutol, pyrazinamide, moxifloxacin, and amikacin). The patient was cured. The isolate from patient 9 had two alterations: a deletion in *ddn* (Tyr29del) and a nucleotide change in *fgd1* (T960C). The strain showed an elevated delamanid MIC and was phenotypically susceptible to six other drugs tested. The patient died. The MIC for the isolates of patients 10 and 6 was above 0.015 but below 0.04 mg/liter (Table 1). This suggests low-level resistance to delamanid (22), which could be due to the combination of various mutations: Ala416Val (*fbiC*), Trp678Gly (*fbiC*), Arg64Ser (*fbiC*), and T960C (*fgd1*).
In summary, in the subset of 10 isolates with polymorphisms in the six targeted genes, six had no elevated MIC in the microdilution, while four isolates had elevated MICs (Table 1). In line with previous studies, we found that Lys270Met in \textit{fgd1} is a natural polymorphism characteristic of \textit{M. tuberculosis} lineage 4.1.2.1, which may (patients 1 and 6) or may not (patient 7) lead to an increased delamanid MIC (19, 34, 35). All 16 strains of lineage 4.1.2.1 showed this lineage-specific marker (Table S1). Furthermore, T960C (\textit{fgd1}) is a synonymous substitution and was found in three other patient isolates which, as expected, did not have a critical MIC. The increase in the delamanid MIC for the isolate of patient 9 was due to the deletion in \textit{ddn} (7). Our results thus suggest that Tyr29del is a natural polymorphism leading to an increased delamanid MIC. Our study was too small to estimate the prevalence of strains that are naturally resistant to delamanid. In 2020, Lee et al. screened 14,876 \textit{M. tuberculosis} strains and found 2 strains with Tyr29del, for a prevalence of 0.013% (36). However, in their study, only the \textit{ddn} gene was screened, and the prevalence of natural resistance could, therefore, be higher.

**Data availability.** WGS data from patients’ \textit{M. tuberculosis} strains shown in Table 1 have been submitted to the NCBI (BioProject accession no. PRJNA300846) (Table S1).

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1,** PDF file, 0.2 MB.

**SUPPLEMENTAL FILE 2,** XLSX file, 0.02 MB.

**ACKNOWLEDGMENTS**

We thank those at all sites who participated, the patients whose data were used in this study, and Marie Ballif for contributing to the data collection and for critical reading of the manuscript. Calculations were performed on UBELIX (http://www.id.unibe.ch/hpc), the HPC cluster at the University of Bern.

This research was supported by the Swiss National Foundation (project grants 153442, 310030_166687, 310030_188888, IZJRZ3_164171, IZLSZ3_170834, and CRSII5_...
177163). The International epidemiology Databases to Evaluate AIDS (IeDEA) is supported by the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Cancer Institute, National Institute of Mental Health, National Institute on Drug Abuse, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute of Diabetes and Kidney Diseases, Fogarty International Center, and National Library of Medicine (Asia-Pacific, U01AI069907; CCASANet, U01AI069923; Central Africa, U01AI069629; East Africa, U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, U01AI069919). R.J.W. receives support from the Francis Crick Institute, which is funded by UKRI, CRUK, and the Wellcome Trust (grants FC0010218, 104803, and 203135). This work is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above.

We have no potential conflicts of interest to disclose.

REFERENCES

1. Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J. 2018. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis (Edinb) 111: 20–30. https://doi.org/10.1016/j.tube.2018.04.008.

2. Esmail A, Sabur NF, Oguchichi D, Dheka K. 2018. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. J Thorac Dis 10:3102–3118. https://doi.org/10.21037/jtd.2018.05.11.

3. WHO. 2019. Consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.

4. EMA. 2018. Deltyba (delamanid): an overview of Deltyba and why it is authorised in the EU. European Medicines Agency, London, United Kingdom.

5. Köser CU, Maurer FP, Kranzer K. 2019. ‘Those who cannot remember the past are condemned to repeat it’: drug-susceptibility testing for bedaquiline and delamanid. Int J Infect Dis 80:S52–S53. https://doi.org/10.1016/j.ijid.2019.02.027.

6. Stinson K, Kurepina N, Yantor A, Fujiwara M, Kawasaki M, Timm J, Shashkina E, Kreiswirth BN, Liu Y, Matsumoto M, Geiter L. 2016. MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother 60:3316–3322. https://doi.org/10.1128/AAC.03014-15.

7. Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM, Niemann S, Uptatel C, Merker M, Trovato A, Hofmann-Thiel S, Hofmann H, Cirillo DM. 2016. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system. J Antimicrob Chemother 71:1532–1539. https://doi.org/10.1093/jac/dkw044.

8. Hoffmann H, Koli TA, Hofmann-Thiel S, Merker M, Beckert P, Jaton K, Nedialkova L, Sahalchyk Y, Rothe T, Keller PM, Niemann S. 2016. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis from an African mother. J Antimicrob Chemother 199:337–340. https://doi.org/10.1094/jac-2015-10327le.

9. Keller PM, Homke R, Ritter C, Valsesia G, Bloemberg GV, Böttger EC. 2015. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXST. Antimicrob Agents Chemother 59:4352–4355. https://doi.org/10.1128/AAC.00614-15.

10. WHO. 2018. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. WHO/CDS/TB/2018.5. World Health Organization, Geneva, Switzerland.

11. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466. https://doi.org/10.1371/journal.pmed.0030466.

12. Purwantini E, Mukhopadhyay B. 2009. Conversion of NO2 to NO by reduced coenzyme F420 protects mycobacteria from nitrosative damage. Proc Natl Acad Sci U S A 106:6333–6338. https://doi.org/10.1073/pnas.0812883106.

13. Fujimura M, Kawasaki M, Hariguchi N, Liu Y, Matsumoto M. 2018. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis (Edinb) 108:186–194. https://doi.org/10.1016/j.tube.2017.12.006.

14. Greening C, Ahmed FH, Mohamed AE, Lee BM, Pandey G, Warden AC, Scott C, Oakeshott JG, Taylor MC, Jackson CJ. 2016. Physiology, biochemistry, and applications of F420- and F430-dependent redox reactions. Microbiol Mol Biol Rev 80:451–493. https://doi.org/10.1128/MMBR.00070-15.

15. Van den Bossche A, Varet H, Sury A, Simeorno O, Legendre R, Coppey J, Mathys V, Ceyssens PJ. 2019. Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid. Tuberculosis (Edinb) 117:18–23. https://doi.org/10.1016/j.tube.2019.05.002.

16. Rifat D, Li S-Y, Loerger T, Lanoix J-P, Lee J, Bashar G, Sacchettni J, Nuememberger E. 2018. Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in Mycobacterium tuberculosis. bioRxiv. https://doi.org/10.1101/457754.

17. Bashiri G, Antoney J, Jirgis EMM, Shah MV, Ney B, Coppel J, Stuteley SM, Sreebhavan S, Palmer B, Middleditch M, Tokuriki N, Greening C, Scott C, Baker EN, Jackson CJ. 2019. A revised biosynthetic pathway for the cofactor F430 in prokaryotes. Nat Commun 10:1558. https://doi.org/10.1038/s41467-019-09534-x.

18. Bloemberg GV, Keller PM, Stucki D, Stuckia D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Homke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC. 2015. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 373:1986–1988. https://doi.org/10.1056/NEJMc1505196.

19. Feuerriegel S, Köser CU, Bau D, Rusch-Gerdes S, Summers DK, Archer JA, Marti-Renom MA, Niemann S. 2011. Impact of Fgd1 and ddn diversity in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. Ann Lab Med 38:563–568. https://doi.org/10.3343/alm.2011.38.6.563.

20. Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H. 2017. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother 61:e00900-17. https://doi.org/10.1128/AAC.00900-17.

21. Polsfuss S, Hofmann-Thiel S, Merker M, Krieger D, Niemann S, Rüssmann H, Schönfeld N, Hofmann H, Kranzer K. 2019. Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment. Clin Infect Dis 69:1229–1231. https://doi.org/10.1093/cid/ciz074.
Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA); ART Cohort Collaboration; Brinkhof MWG, Egger M, Boullé A, May M, Hosseinipour M, Sprinz E, Braithwaite P, Dabis F, Reiss P, Bangsberg DR, Rickenbach M, Miro JM, Myler L, Mofcroft A, Nash D, Keiser O, Pascoe M, van der Bortgh S, Schechter M. 2007. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 45:1518–1521. https://doi.org/10.1086/522986.

Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotiebieng M, Diero L, Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AG, Collantes J, Avihingsanon A, Kawkiniarong K, Reinhard M, Hörnke R, Huebner R, Gagneux S, Böttger EC, Egger M, International epidemiological Databases to Evaluate AIDS (IeDEA) consortium. 2019. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis 19:298–307. https://doi.org/10.1016/S1473-3099(18)30673-X.

Gygli SM, Keller PM, Ballif M, Blöchinger N, Hörnke R, Reinhard M, Loiseau C, Ritter C, Sander P, Borrell S, Collantes Loo J, Avihingsanon A, Gnokoro J, Yotiebieng M, Egger M, Gagneux S, Böttger EC. 2019. Whole-genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother 63:e02175-18. https://doi.org/10.1128/AAC.02175-18.

Phelan JE, O’Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, O’Grady J, McNerney R, Hibberd ML, Vireiros M, Huggett JF, Clark TG. 2019. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med 12:27.https://doi.org/10.1186/s13073-019-0650-x.

Coll F, Phelan J, Hill-Cawthorne GA, Nair MB, Mallard K, Ali S, Abdallah AM, Alghamdi S, Alsomali M, Ahmed AO, Portelli S, Oppong Y, Alves A, Bessa TB, Campino S, Caws M, Chatterjee A, Crampin AC, Dheda K, Furnham N, Glynn JR, Grandjean L, Ha DM, Hasan R, Hasan Z, Hibberd ML, Joloba M, Jones-Lopez EC, Matsumoto T, Miranda A, Moore DJ, Miotto P, Parkhill J, Penha C, Perdigao J, Portugal I, Rchiad M, Rickenbach M, Sander P, Borrell S, Collantes J, Avihingsanon A, Gnokoro J, Yotiebieng M, Egger M, Gagneux S, Böttger EC. 2019. Whole-genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother 63:e02175-18. https://doi.org/10.1128/AAC.02175-18.

Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754–1760. https://doi.org/10.1093/bioinformatics/btp234.

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078–2079. https://doi.org/10.1093/bioinformatics/btp352.

Lee BM, Harold LK, Almeida DV, Afiat-Jumou L, Aung HL, Forde BM, Hards K, Pidot SJ, Ahmed FH, Mohamed AE, Taylor MC, West NP, Stinear TP, Greening C, Beaton SA, Nuernberger EL, Cook GM, Jackson CJ. 2020. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering. PLoS Pathog 16:e1008287. https://doi.org/10.1371/journal.ppat.1008287.